Attached files
| file | filename |
|---|---|
| 8-K - 8-K - BIOMARIN PHARMACEUTICAL INC | bmrn-8k_20160428.htm |
Exhibit 99.1
|
Contact: |
|
|
|
Investors: |
|
Media: |
|
Traci McCarty |
|
Debra Charlesworth |
|
BioMarin Pharmaceutical Inc. |
|
BioMarin Pharmaceutical Inc. |
|
(415) 455-7558 |
|
(415) 455-7451 |
FOR IMMEDIATE RELEASE
BioMarin Announces First Quarter 2016 Financial Results
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million
-Vimizim Net Product Revenue Increases 43.5% Y/Y and Contributes $72.6 million in the First Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $315 to $340 million
- Kuvan Net Product Revenue Contributes $76.9 million in the First Quarter 2016; $60.0 million from North America and $16.9 million from Newly Acquired ex-North American Territories
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)
|
|
|
Three Months Ended March 31, |
|
|||||||||
|
|
|
2016 |
|
|
2015 |
|
|
% Change |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total BioMarin Revenue |
|
$ |
236.7 |
|
|
$ |
202.9 |
|
|
|
16.7 |
% |
|
Vimizim Net Product Revenue |
|
|
72.6 |
|
|
|
50.6 |
|
|
|
43.5 |
% |
|
Naglazyme Net Product Revenue |
|
|
65.4 |
|
|
|
78.2 |
|
|
|
(16.4 |
)% |
|
Kuvan Net Product Revenue |
|
|
76.9 |
|
|
|
50.2 |
|
|
|
53.2 |
% |
|
Aldurazyme Net Product Revenue |
|
|
16.4 |
|
|
|
18.2 |
|
|
|
(9.9 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Net Loss |
|
$ |
(27.2 |
) |
|
$ |
(25.4 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Net Loss |
|
$ |
(85.1 |
) |
|
$ |
(67.5 |
) |
|
|
|
|
|
GAAP Net Loss per Share - Basic and Diluted |
|
$ |
(0.53 |
) |
|
$ |
(0.43 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalents and investments |
|
$ |
771.3 |
|
|
$ |
1,018.3 |
|
|
|
|
|
SAN RAFAEL, Calif., April 28, 2016 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the first quarter ended March 31, 2016. Non-GAAP net loss was $27.2 million for the quarter ended March 31, 2016, compared to non-GAAP net loss of $25.4 million for the first quarter of 2015. GAAP net loss was $85.1 million, or $0.53 per basic and diluted share for the first quarter of 2016, compared to GAAP net loss of $67.5 million, or $0.43 per basic and diluted share, for the first quarter of 2015.
1
Total BioMarin Revenue was $236.7 million for the first quarter of 2016, an increase of 16.7% compared to the same period in 2015. This strong result was driven by year over year growth of 43.5% and 53.2% of Vimizim and Kuvan, respectively. Kuvan revenue from ex-North America territories since BioMarin acquired worldwide rights in January 2016 contributed $16.9 million and revenues in North America contributed $60.0 million in the quarter. Naglazyme patient growth was 8.5% compared to a year ago, the 40th straight quarter since the product was launched in 2005. Naglazyme revenue in the first quarter 2016 was lower than revenue in the first quarter 2015 primarily due to the timing of central government orders from Latin America.
As of March 31, 2016, BioMarin had cash, cash equivalents and investments totaling $771.3 million, as compared to $1,018.3 million on December 31, 2015.
Commenting on the quarter, Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin said, “Our commercial base business is robust and is expected to generate over one billion dollars in revenues this year. Prospects for new product launches in 2017 increased during the quarter due to positive data readouts for cerliponase alfa and pegvaliase that we expect will lead to two new product filings later this year. In addition, at our recent Research and Development Day for analysts and investors, we highlighted very encouraging preliminary data from our gene therapy product BMN 270 for hemophilia A and robust 12 month data with vosoritide for achondroplasia. If the data from these programs continue to mature as we hope, we believe that these products could each ultimately drive a billion dollars in revenue when commercialized. Finally, we continue to expect to manage this growing business with the goal of achieving non-GAAP break-even or better in 2017 regardless of the regulatory outcome of Kyndrisa in Europe.”
Net Product Revenue (in millions of U.S. dollars, unaudited)
Total Revenue
|
|
|
Three Months Ended March 31, |
|
|||||||||||||
|
|
|
2016 |
|
|
2015 |
|
|
$ Change |
|
|
% Change |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vimizim (1) |
|
$ |
72.6 |
|
|
$ |
50.6 |
|
|
$ |
22.0 |
|
|
|
43.5 |
% |
|
Naglazyme (1) |
|
|
65.4 |
|
|
|
78.2 |
|
|
|
(12.8 |
) |
|
|
(16.4 |
)% |
|
Kuvan (2) |
|
|
76.9 |
|
|
|
50.2 |
|
|
|
26.7 |
|
|
|
53.2 |
% |
|
Aldurazyme |
|
|
16.4 |
|
|
|
18.2 |
|
|
|
(1.8 |
) |
|
|
(9.9 |
)% |
|
Firdapse |
|
|
4.1 |
|
|
|
4.1 |
|
|
|
- |
|
|
|
0.0 |
% |
|
Net product revenues |
|
|
235.4 |
|
|
|
201.3 |
|
|
|
34.1 |
|
|
|
16.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative agreement revenues |
|
|
0.2 |
|
|
|
0.4 |
|
|
|
(0.2 |
) |
|
|
|
|
|
Royalty, license and other revenues |
|
|
1.1 |
|
|
|
1.2 |
|
|
|
(0.1 |
) |
|
|
|
|
|
Total BioMarin revenues |
|
$ |
236.7 |
|
|
$ |
202.9 |
|
|
$ |
33.8 |
|
|
|
16.7 |
% |
|
(1) |
Vimizim and Naglazyme revenues experience quarterly fluctuations primarily due to the timing of government ordering patterns in certain countries. The Company does not believe these fluctuations reflect a change in underlying demand. |
|
(2) |
Growth in North America contributed $60.0 million in the first quarter with an additional $16.9 million coming from newly acquired ex-North American territories. |
Reconciliation of Aldurazyme Revenues
|
|
|
Three Months Ended March 31, |
|
|||||||||||||
|
|
|
2016 |
|
|
2015 |
|
|
$ Change |
|
|
% Change |
|
||||
|
Aldurazyme revenue reported by Genzyme |
|
$ |
52.8 |
|
|
$ |
53.4 |
|
|
$ |
(0.6 |
) |
|
|
(1.1 |
)% |
|
|
|
Three Months Ended March 31, |
|
|||||||||
|
|
|
2016 |
|
|
2015 |
|
|
$ Change |
|
|||
|
Royalties earned from Genzyme |
|
$ |
21.5 |
|
|
$ |
22.3 |
|
|
$ |
(0.8 |
) |
|
Net product transfer revenues (3) |
|
|
(5.1 |
) |
|
|
(4.1 |
) |
|
|
(1.0 |
) |
|
Total Aldurazyme net product revenues |
|
$ |
16.4 |
|
|
$ |
18.2 |
|
|
$ |
(1.8 |
) |
2
2016 Financial Guidance
Revenue Guidance ($ in millions)
|
Item |
|
|
|
|
|
|
|
Provided February 25, 2016 |
|
Updated April 28, 2016 |
|
Total BioMarin Revenues |
|
$1,050 to $1,100 |
|
Unchanged |
|
Vimizim Net Product Revenue |
|
$300 to $330 |
|
$315 to $340 |
|
Naglazyme Net Product Revenue |
|
$290 to $320 |
|
Unchanged |
|
Kuvan Net Product Revenue |
|
$320 to $350 |
|
Unchanged |
Select Income Statement Guidance ($ in millions, except percentages)
|
Item |
|
|
|
|
|
|
|
Provided February 25, 2016 |
|
Updated April 28, 2016 |
|
Cost of Sales (% of Total Revenue) |
|
18.0% to 19.0% |
|
Unchanged |
|
Selling, General and Admin. Expense |
|
$470 to $490 |
|
Unchanged |
|
Research and Development Expense |
|
$680 to $720 |
|
Unchanged |
|
Non - GAAP Net Loss |
|
$(75) to $(100) |
|
Unchanged |
|
GAAP Net Loss |
|
$(400) to $(430) |
|
$(355) to $(385)* |
*GAAP Net Loss guidance updated April 28, 2016 based on impact of final purchase accounting treatment for the PKU franchise acquisition from Merck that closed in the first quarter 2016.
Key Program Updates at R&D Day April 20, 2016
|
· |
BMN 270 gene therapy product for hemophilia A: The Company provided encouraging preliminary data from an ongoing Phase 1/2 clinical trial with BMN 270, an investigational gene therapy treatment for hemophilia A. A total of eight patients with severe hemophilia A received a single dose of BMN 270, six of whom have been treated at the highest dose of 6 x 1013 vector genomes (VG)/kilogram (kg), and to date, post-treatment follow-up ranges from five to 16 weeks. As stated at R&D Day, patients at the highest dose experienced increasing Factor VIII activity levels ranging between 4% and 60% (as a percentage of normal calculated based on the numbers of International Units (IU) per milliliter of whole blood), with five of six patients treated at the high dose now over 5% and two of six at over 50%. All high dose patients improved from severe to either moderate, mild or normal range in terms of factor levels based on World Federation of Hemophilia criteria. (See BioMarin press release from April 20, 2016 for further details.) |
|
· |
Vosoritide for achondroplasia: The Company provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most common form of dwarfism. After 12 months of daily dosing at 15 µg/kg/day, the cohort 3 patients (n=10) experienced a 46% or 1.9 cm/year increase in mean annualized growth velocity from baseline (p-value = 0.02). These findings provide evidence of durability of effect consistent with previously presented 6-month data for these patients, which demonstrated an annualized increase of 50% or 2.0 cm/year in mean annualized growth velocity. In addition, 6-month data for 12 patients who were initiated on a lower dose and switched to 15 µg/kg/day showed an increase of 65% or 2.3 cm/year in mean annualized growth velocity from baseline (p-value = 0.002). (See BioMarin press release from April 20, 2016 for further details.) |
3
|
· |
Cerliponase alfa for CLN2, late-infantile form of Batten disease: Complete results from the Phase 1/2 study of cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1), for the treatment of patients with late-infantile neuronal ceroid lipofuscinosis type 2 (NCL-2), a form of Batten disease were announced at the WORLD LSD Symposium on March 2, 2016. Based on the robust data results announced at that meeting, the Company shared plans to submit in the U.S. and E.U. for regulatory approval mid-year 2016. (See BioMarin press release from March 2, 2016 for further details.) |
|
· |
Pegvaliase for phenylketonuria (PKU): Pivotal results for the Phase 3 PRISM-2 study (formerly referred to as 165-302) that pegvaliase met the primary endpoint of change in blood Phe compared with placebo (p<0.0001) were announced March 21, 2016. The pegvaliase treated group maintained mean blood Phe levels at 527.2 umol/L compared to their RDT baseline of 503.9 umol/L, whereas the placebo treated group mean blood Phe levels increased to 1385.7 umol/L compared to their RDT baseline of 536.0 umol/L. The treatment effect demonstrated in this study represents an approximately 62% improvement in blood Phe compared to placebo. Based on the supportive data results, the Company plans to submit a Biologics License Application (BLA) to U.S. FDA in the second half of 2016. (See BioMarin press release from March 21, 2016 for further details.) |
Conference Call Details
BioMarin will host a conference call and webcast to discuss first quarter 2016 financial results today, Thursday, April 28, at 4:30 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.BMRN.com.
U.S. / Canada Dial-in Number: 877.303.6313
International Dial-in Number: 631.813.4734
Conference ID: 86095021
Replay Dial-in Number: 855.859.2056
Replay International Dial-in Number: 404.537.3406
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Forward-Looking Statement
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Vimizim, Naglazyme, Kuvan, Firdapse, and Aldurazyme; the financial performance of the BioMarin as a whole; the timing of BioMarin's clinical trials; the continued clinical development and commercialization of Vimizim, Naglazyme, Kuvan, Firdapse, Aldurazyme and its product candidates; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the commercialization of Vimizim, Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; actual sales of Vimizim, Naglazyme, Kuvan, Firdapse and Aldurazyme; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2015 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin®, Naglazyme®, Kuvan®, Firdapse® and Vimizim® are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. KyndrisaTM is a trademark of BioMarin Pharmaceutical Inc. Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.
4
CONDENSED CONSOLIDATED BALANCE SHEETS
March 31, 2016 and December 31, 2015
(In thousands of U.S. dollars, except share and per share amounts)
|
|
|
March 31, 2016 |
|
|
December 31, 2015(1) |
|
||
|
ASSETS |
|
(unaudited) |
|
|
|
|||
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
270,453 |
|
|
$ |
397,040 |
|
|
Short-term investments |
|
|
186,400 |
|
|
|
195,579 |
|
|
Accounts receivable, net (allowance for doubtful accounts: $167 and $93, at March 31, 2016 and December 31, 2015, respectively) |
|
|
180,751 |
|
|
|
164,959 |
|
|
Inventory |
|
|
296,979 |
|
|
|
271,683 |
|
|
Other current assets |
|
|
58,207 |
|
|
|
60,378 |
|
|
Total current assets |
|
|
992,790 |
|
|
|
1,089,639 |
|
|
Noncurrent assets: |
|
|
|
|
|
|
|
|
|
Long-term investments |
|
|
314,404 |
|
|
|
425,652 |
|
|
Property, plant and equipment, net |
|
|
716,916 |
|
|
|
704,207 |
|
|
Intangible assets, net |
|
|
1,177,232 |
|
|
|
683,996 |
|
|
Goodwill |
|
|
197,039 |
|
|
|
197,039 |
|
|
Long-term deferred tax assets |
|
|
243,212 |
|
|
|
220,191 |
|
|
Other assets |
|
|
25,400 |
|
|
|
408,644 |
|
|
Total assets |
|
$ |
3,666,993 |
|
|
$ |
3,729,368 |
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
|
290,562 |
|
|
|
392,511 |
|
|
Short-term contingent acquisition consideration payable |
|
|
97,449 |
|
|
|
52,946 |
|
|
Total current liabilities |
|
|
388,011 |
|
|
|
445,457 |
|
|
Noncurrent liabilities: |
|
|
|
|
|
|
|
|
|
Long-term convertible debt |
|
|
668,009 |
|
|
|
662,286 |
|
|
Long-term contingent acquisition consideration payable |
|
|
135,275 |
|
|
|
32,663 |
|
|
Long-term deferred tax liabilities |
|
|
143,527 |
|
|
|
143,527 |
|
|
Other long-term liabilities |
|
|
41,935 |
|
|
|
44,588 |
|
|
Total liabilities |
|
|
1,376,757 |
|
|
|
1,328,521 |
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
|
Common stock, $0.001 par value: 250,000,000 shares authorized at March 31, 2016 and December 31, 2015: 162,243,016 and 161,526,044 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively |
|
|
163 |
|
|
|
162 |
|
|
Additional paid-in capital |
|
|
3,410,297 |
|
|
|
3,414,837 |
|
|
Company common stock held by Nonqualified Deferred Compensation Plan |
|
|
(13,560 |
) |
|
|
(13,616 |
) |
|
Accumulated other comprehensive income |
|
|
47 |
|
|
|
21,033 |
|
|
Accumulated deficit |
|
|
(1,106,711 |
) |
|
|
(1,021,569 |
) |
|
Total stockholders’ equity |
|
|
2,290,236 |
|
|
|
2,400,847 |
|
|
Total liabilities and stockholders’ equity |
|
$ |
3,666,993 |
|
|
$ |
3,729,368 |
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
December 31, 2015 balances were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the U.S. Securities and Exchange Commission on February 29, 2016. |
5
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended March 31, 2016 and 2015
(In thousands of U.S. dollars, except per share amounts)
(Unaudited)
|
|
|
Three Months Ended March 31, |
|
|||||
|
|
|
2016 |
|
|
2015 |
|
||
|
REVENUES: |
|
|
|
|
|
|
|
|
|
Net product revenues |
|
$ |
235,357 |
|
|
$ |
201,312 |
|
|
Collaborative agreement revenues |
|
|
233 |
|
|
|
376 |
|
|
Royalty, license and other revenues |
|
|
1,146 |
|
|
|
1,232 |
|
|
Total revenues |
|
|
236,736 |
|
|
|
202,920 |
|
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
43,118 |
|
|
|
30,998 |
|
|
Research and development |
|
|
158,793 |
|
|
|
142,074 |
|
|
Selling, general and administrative |
|
|
105,300 |
|
|
|
92,806 |
|
|
Intangible asset amortization and contingent consideration |
|
|
10,442 |
|
|
|
2,902 |
|
|
Total operating expenses |
|
|
317,653 |
|
|
|
268,780 |
|
|
NET LOSS FROM OPERATIONS |
|
|
(80,917 |
) |
|
|
(65,860 |
) |
|
Equity in the loss of BioMarin/Genzyme LLC |
|
|
(135 |
) |
|
|
(150 |
) |
|
Interest income |
|
|
1,571 |
|
|
|
683 |
|
|
Interest expense |
|
|
(9,843 |
) |
|
|
(9,462 |
) |
|
Debt conversion expense |
|
|
— |
|
|
|
(163 |
) |
|
Other income |
|
|
198 |
|
|
|
249 |
|
|
NET LOSS BEFORE INCOME TAXES |
|
|
(89,126 |
) |
|
|
(74,703 |
) |
|
Benefit from income taxes |
|
|
(3,984 |
) |
|
|
(7,202 |
) |
|
NET LOSS |
|
$ |
(85,142 |
) |
|
$ |
(67,501 |
) |
|
NET LOSS PER SHARE, BASIC AND DILUTED |
|
$ |
(0.53 |
) |
|
$ |
(0.43 |
) |
|
Weighted average common shares outstanding, basic and diluted |
|
|
161,548 |
|
|
|
157,612 |
|
|
|
|
|
|
|
|
|
|
|
6
The results for the three months ended March 31, 2016 and 2015 include both GAAP net loss and non-GAAP loss. As used in this release, non-GAAP loss is based on GAAP net loss and the guidance for full-year net loss before interest, taxes, depreciation and amortization and further adjusted to exclude certain non-cash stock-based compensation expense, non-cash contingent consideration expense and certain other specified items, as detailed below (non-GAAP loss).
BioMarin believes that the non-GAAP information in this press release is useful to investors, taken in conjunction with BioMarin’s GAAP information because it provides additional information regarding the performance of BioMarin’s core ongoing business, Naglazyme, Vimizim, Kuvan, Aldurazyme and Firdapse and development of its pipeline. By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the Company believes that the additional information enhances investors’ overall understanding of the Company’s business and prospects for the future. Further, the Company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes.
The following table presents the reconciliation of GAAP to non-GAAP financial metrics:
Reconciliation of GAAP Net Loss to Non-GAAP Loss
(In millions of U.S. dollars)
(Unaudited)
|
|
Three Months Ended |
|
|
Year Ending |
|||||
|
|
March 31, |
|
|
December 31, 2016 |
|||||
|
|
2016 |
|
|
2015 |
|
|
Guidance |
||
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Net Loss |
$ |
(85.1 |
) |
|
$ |
(67.5 |
) |
|
$(355) to $(385) |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
8.2 |
|
|
|
8.8 |
|
|
35.0 |
|
Benefit from income taxes |
|
(4.0 |
) |
|
|
(7.2 |
) |
|
(20.0) - (57.0) |
|
Depreciation expense |
|
13.1 |
|
|
|
7.9 |
|
|
35.0 - 45.0 |
|
Amortization expense |
|
7.5 |
|
|
|
2.6 |
|
|
45.0 |
|
Stock-based compensation expense |
|
30.2 |
|
|
|
22.7 |
|
|
140.0 - 167.0 |
|
Contingent consideration expense (1) |
|
2.9 |
|
|
|
0.3 |
|
|
45.0 - 50.0 |
|
Acquisition expenses (2) |
|
— |
|
|
|
7.0 |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP Loss |
$ |
(27.2 |
) |
|
$ |
(25.4 |
) |
|
$(75) to $(100) |
|
|
(1) |
Represents the expense associated with the change in the fair value of contingent acquisition consideration payable for the period, resulting from changes in estimated probabilities and timing of achieving certain developmental milestones. |
|
|
(2) |
The $7.0 million in the three months ended March 31, 2015, represents transaction expenses for the acquisition of Prosensa Holding N.V. |
7
The following reconciliation of the Company’s GAAP Condensed Consolidated Statements of Operations to non-GAAP Net Loss provides the details of the effects of the non-GAAP adjustments on the components of the Company’s operating results for each of the periods presented. Management believes that providing the effects of the non-GAAP adjustments on the components of operating results is useful to investors and, when reviewed in conjunction with the Company’s GAAP results, provides additional information regarding key drivers of the Company’s core operations. The Company uses operating results on both a GAAP and a non-GAAP basis internally for operating, budgeting and financial planning purposes.
BIOMARIN PHARMACEUTICAL INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND RECONCILIATION OF non-GAAP ADJUSTMENTS
Three Months Ended March 31, 2016 and 2015
(In millions of U.S. dollars)
(Unaudited)
|
|
Three Months Ended March 31, |
|
|||||||||||||||||||||||||||||
|
|
2016 |
|
|
2015 |
|
||||||||||||||||||||||||||
|
|
|
|
|
|
Non-GAAP Adjustments |
|
|
|
|
|
|
|
|
|
|
Non-GAAP Adjustments |
|
|
|
|
|
||||||||||
|
|
GAAP |
|
|
Interest, Taxes, Depreciation and Amortization |
|
|
Stock-Based Compensation, Contingent Consideration and Other Adjustments |
|
|
Non-GAAP |
|
|
GAAP |
|
|
Interest, Taxes, Depreciation and Amortization |
|
|
Stock-Based Compensation, Contingent Consideration and Other Adjustments |
|
|
Non-GAAP |
|
||||||||
|
REVENUES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net product revenues |
$ |
235.4 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
235.4 |
|
|
$ |
201.3 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
201.3 |
|
|
Collaborative agreement revenues |
|
0.2 |
|
|
|
— |
|
|
|
— |
|
|
|
0.2 |
|
|
|
0.4 |
|
|
|
— |
|
|
|
— |
|
|
|
0.4 |
|
|
Royalty, license and other revenues |
|
1.1 |
|
|
|
— |
|
|
|
— |
|
|
|
1.1 |
|
|
|
1.2 |
|
|
|
— |
|
|
|
— |
|
|
|
1.2 |
|
|
Total revenues |
|
236.7 |
|
|
|
— |
|
|
|
— |
|
|
|
236.7 |
|
|
|
202.9 |
|
|
|
— |
|
|
|
— |
|
|
|
202.9 |
|
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
|
43.1 |
|
|
|
— |
|
|
|
(1.6 |
) |
|
|
41.5 |
|
|
|
31.0 |
|
|
|
— |
|
|
|
(1.3 |
) |
|
|
29.7 |
|
|
Research and development |
|
158.8 |
|
|
|
(7.4 |
) |
|
|
(13.7 |
) |
|
|
137.7 |
|
|
|
142.1 |
|
|
|
(3.6 |
) |
|
|
(10.0 |
) |
|
|
128.5 |
|
|
Selling, general and administrative |
|
105.3 |
|
|
|
(5.7 |
) |
|
|
(14.9 |
) |
|
|
84.7 |
|
|
|
92.8 |
|
|
|
(4.3 |
) |
|
|
(18.4 |
) |
|
|
70.1 |
|
|
Intangible asset amortization and contingent consideration |
|
10.4 |
|
|
|
(7.5 |
) |
|
|
(2.9 |
) |
|
|
— |
|
|
|
2.9 |
|
|
|
(2.6 |
) |
|
|
(0.3 |
) |
|
|
— |
|
|
Total operating expenses |
|
317.6 |
|
|
|
(20.6 |
) |
|
|
(33.1 |
) |
|
|
263.9 |
|
|
|
268.8 |
|
|
|
(10.5 |
) |
|
|
(30.0 |
) |
|
|
228.3 |
|
|
LOSS FROM OPERATIONS |
|
(80.9 |
) |
|
|
20.6 |
|
|
|
33.1 |
|
|
|
(27.2 |
) |
|
|
(65.9 |
) |
|
|
10.5 |
|
|
|
30.0 |
|
|
|
(25.4 |
) |
|
Equity in the loss of BioMarin/Genzyme LLC |
|
(0.1 |
) |
|
|
— |
|
|
|
— |
|
|
|
(0.1 |
) |
|
|
(0.2 |
) |
|
|
— |
|
|
|
— |
|
|
|
(0.2 |
) |
|
Interest income |
|
1.6 |
|
|
|
(1.6 |
) |
|
|
— |
|
|
|
— |
|
|
|
0.7 |
|
|
|
(0.7 |
) |
|
|
— |
|
|
|
— |
|
|
Interest expense |
|
(9.8 |
) |
|
|
9.8 |
|
|
|
— |
|
|
|
— |
|
|
|
(9.5 |
) |
|
|
9.5 |
|
|
|
— |
|
|
|
— |
|
|
Debt conversion expense |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(0.2 |
) |
|
|
— |
|
|
|
— |
|
|
|
(0.2 |
) |
|
Other income |
|
0.1 |
|
|
|
— |
|
|
|
— |
|
|
|
0.1 |
|
|
|
0.4 |
|
|
|
— |
|
|
|
— |
|
|
|
0.4 |
|
|
LOSS BEFORE INCOME TAXES |
|
(89.1 |
) |
|
|
28.8 |
|
|
|
33.1 |
|
|
|
(27.2 |
) |
|
|
(74.7 |
) |
|
|
19.3 |
|
|
|
30.0 |
|
|
|
(25.4 |
) |
|
Benefit from income taxes |
|
(4.0 |
) |
|
|
4.0 |
|
|
|
— |
|
|
|
— |
|
|
|
(7.2 |
) |
|
|
7.2 |
|
|
|
— |
|
|
|
— |
|
|
NET LOSS |
$ |
(85.1 |
) |
|
$ |
24.8 |
|
|
$ |
33.1 |
|
|
$ |
(27.2 |
) |
|
$ |
(67.5 |
) |
|
$ |
12.1 |
|
|
$ |
30.0 |
|
|
$ |
(25.4 |
) |
8
The following summarizes the reconciliation of the components of the non-GAAP adjustments to Cost of sales, Research and development and Selling, general and administrative expenses from the GAAP to the non-GAAP presentation (in millions of U.S. dollars, unaudited):
|
|
Three Months Ended March 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
|
|
|
|
|
|
|
|
|
|
Cost of sales - GAAP |
$ |
43.1 |
|
|
$ |
31.0 |
|
|
Less: non-GAAP adjustments: |
|
|
|
|
|
|
|
|
Stock-based compensation |
|
(1.6 |
) |
|
|
(1.3 |
) |
|
Cost of sales - non-GAAP |
$ |
41.5 |
|
|
$ |
29.7 |
|
|
|
Three Months Ended March 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
|
|
|
|
|
|
|
|
|
|
Research and development - GAAP |
$ |
158.8 |
|
|
$ |
142.1 |
|
|
Less: non-GAAP adjustments: |
|
|
|
|
|
|
|
|
Stock-based compensation |
|
(13.7 |
) |
|
|
(10.0 |
) |
|
Depreciation |
|
(7.4 |
) |
|
|
(3.6 |
) |
|
Research and development - non-GAAP |
$ |
137.7 |
|
|
$ |
128.5 |
|
|
|
Three Months Ended March 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative - GAAP |
$ |
105.3 |
|
|
$ |
92.8 |
|
|
Less: non-GAAP adjustments: |
|
|
|
|
|
|
|
|
Stock-based compensation |
|
(14.9 |
) |
|
|
(11.4 |
) |
|
Depreciation |
|
(5.7 |
) |
|
|
(4.3 |
) |
|
Acquisition expenses |
|
- |
|
|
|
(7.0 |
) |
|
Selling, general and administrative - non-GAAP |
$ |
84.7 |
|
|
$ |
70.1 |
|
|
|
Three Months Ended March 31, |
|
|||||
|
|
2016 |
|
|
2015 |
|
||
|
|
|
|
|
|
|
|
|
|
Intangible asset amortization and contingent consideration - GAAP |
$ |
10.4 |
|
|
$ |
2.9 |
|
|
Less: non-GAAP adjustments |
|
|
|
|
|
|
|
|
Intangible asset amortization |
|
(7.5 |
) |
|
|
(2.6 |
) |
|
Contingent consideration |
|
(2.9 |
) |
|
|
(0.3 |
) |
|
Intangible asset amortization and contingent consideration - non-GAAP |
$ |
— |
|
|
$ |
— |
|
###
9